UniProtKB/Swiss-Prot P60709: Variant p.Pro70Ala

• Variant information
• Sequence information
• Literature citations
• All

Variant information

Variant position: 70 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: LP/P [Disclaimer: Variants classification is intended for research purposes only, not for clinical and diagnostic use. The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant.] The variants are classified into three categories: LP/P, LB/B and US.

• LP/P: likely pathogenic or pathogenic.
• LB/B: likely benign or benign.
• US: uncertain significance

Residue change: From Proline (P) to Alanine (A) at position 70 (P70A, p.Pro70Ala). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: Change from medium size and hydrophobic (P) to small size and hydrophobic (A) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

• Lowest score: -4 (low probability of substitution).
• Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description: In BRWS1; likely pathogenic. Any additional useful information about the variant.

Sequence information

Variant position: 70 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 375 The length of the canonical sequence.
Location on the sequence: KDSYVGDEAQSKRGILTLKY P IEHGIVTNWDDMEKIWHHTF The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

• Type: the type of sequence feature.
• Positions: endpoints of the sequence feature.
• Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 375	Actin, cytoplasmic 1
Chain	2 – 375	Actin, cytoplasmic 1, N-terminally processed
Modified residue	73 – 73	Tele-methylhistidine
Modified residue	84 – 84	N6-methyllysine
Cross	50 – 50	(Microbial infection) Isoglutamyl lysine isopeptide (Lys-Glu) (interchain with E-270); by Vibrio toxins RtxA and VgrG1
Mutagenesis	69 – 69	Y -> A. Decreased interaction with SETD3.
Mutagenesis	71 – 71	I -> A. Decreased interaction with SETD3.
Mutagenesis	71 – 71	I -> A. Impaired methylation by SETD3.
Mutagenesis	73 – 73	H -> A. Abolished methylation by SETD3.
Mutagenesis	73 – 73	H -> K. Weak methylation by a A-256 or V-256 SETD3 mutant. High methylation by a F-256 and A-274 SETD3 mutant.
Mutagenesis	74 – 74	G -> A. Impaired methylation by SETD3.
Mutagenesis	79 – 79	W -> E. Does not affect methylation by SETD3.
Mutagenesis	80 – 80	D -> A. Decreased interaction with SETD3.
Mutagenesis	81 – 81	D -> A. Decreased interaction with SETD3.
Mutagenesis	82 – 82	M -> A. Decreased interaction with SETD3.
Beta strand	68 – 70

Literature citations

Could Dissimilar Phenotypic Effects of ACTB Missense Mutations Reflect the Actin Conformational Change? Two Novel Mutations and Literature Review.
Sandestig A.; Green A.; Jonasson J.; Vogt H.; Wahlstroem J.; Pepler A.; Ellnebo K.; Biskup S.; Stefanova M.;
Mol. Syndromol. 9:259-265(2019)
Cited for: VARIANT BRWS1 ALA-70; VARIANT THC8 PHE-171;